Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29431315 | 0.83 | CYP1A2 (0.62) | SMN1; SMN2LMNAP2RX7CASP3SENP8 | |
| SCHEMBL950737 | 0.83 | CYP1A2 (0.62) | SMN1; SMN2LMNAP2RX7CASP3SENP8 | |
| SCHEMBL3110927 | 0.81 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAP2RX7CASP3SENP8 | |
| SCHEMBL16540510 | 0.81 | P2RX7 (0.51) | SMN1; SMN2LMNAP2RX7CASP3SENP8 | |
| SCHEMBL1515657 | 0.79 | KDM4E (0.44) | P2RX7CYP1A2KDM4EMAPTL3MBTL1 | |
| SCHEMBL27612752 | 0.79 | KDM4E (0.44) | P2RX7CYP1A2KDM4EMAPTHTT | |
| SCHEMBL28121426 | 0.79 | CASP3 (0.46) | SMN1; SMN2LMNAP2RX7CASP3SENP8 | |
| SCHEMBL7633274 | 0.79 | LMNA (0.58) | SMN1; SMN2LMNAP2RX7CASP3SENP8 | |
| SCHEMBL999250 | 0.78 | P2RX7 (0.50) | SMN1; SMN2P2RX7CYP1A2KDM4EMAPT | |
| SCHEMBL20185612 | 0.77 | CASP3 (0.55) | SMN1; SMN2LMNACASP3SENP8SENP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11737463-B2 | Pyridine and pyrazine compounds | BASF SE (DE) | 2023-08-29 | — | — | US | disclosed |
| CN-109415321-B | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-114269721-A | Compounds for the treatment of respiratory diseases | TMEM16A有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20210145002-A1 | PYRIDINE AND PYRAZINE COMPOUNDS | BASF SE (DE) | 2021-05-20 | — | — | US | disclosed |
| WO-2019062949-A1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | 上海海和药物研究开发有限公司 | 2019-04-04 | — | — | WO | disclosed |
| EP-2519524-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | Hutchison Medipharma Limited (CN) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011079804-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LIMITED (CN) | 2011-07-07 | — | — | WO | disclosed |
| US-20060160794-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY | 2006-07-20 | — | — | US | disclosed |
| EP-1638944-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000821-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11737463-B2 | Pyridine and pyrazine compounds | NDUFS5, IL5, NDUFS4 | SMN1; SMN2 3876/4885LMNA 4043/4885P2RX7 42/4885 |
| US-20210145002-A1 | PYRIDINE AND PYRAZINE COMPOUNDS | NDUFS5, IL5, NDUFS4 | SMN1; SMN2 3876/4885LMNA 4043/4885P2RX7 42/4885 |
| US-20060160794-A1 | Tachykinin receptor antagonists | TACR1, TACR2, PROKR1 | SMN1; SMN2 2953/4885LMNA 4479/4885P2RX7 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.